Candel Therapeutics (CADL) Cash & Equivalents (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Cash & Equivalents data on file, last reported at $119.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 16.64% year-over-year to $119.7 million; the trailing twelve-month figure through Dec 2025 stood at $119.7 million (up 16.64% YoY), and the FY2025 full-year result was $119.7 million, up 16.64% from the prior year.
• Cash & Equivalents advanced to $119.7 million in Q4 2025, from $87.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $119.7 million in Q4 2025 to a low of $16.6 million in Q3 2024.
• A 5-year average of $67.3 million and a median of $77.2 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 61.49% in 2024 and jumped 425.2% in 2025, its largest moves.
• Tracing CADL's Cash & Equivalents over 5 years: stood at $82.6 million in 2021, then fell by 15.23% to $70.1 million in 2022, then slumped by 49.45% to $35.4 million in 2023, then surged by 189.88% to $102.7 million in 2024, then advanced by 16.64% to $119.7 million in 2025.
• Business Quant data shows CADL's Cash & Equivalents at $119.7 million in Q4 2025, $87.0 million in Q3 2025, and $100.7 million in Q2 2025.